Idogen is a Swedish biotechnology company based in Lund. The Idogen share has been listed on Nasdaq First Growth market since the 4th of June 2020 under the ticker IDOGEN and is traded through banks and stockbrokers.
Idogen develops tolerogenic cell therapies to counteract attacks by the patient’s immune system on biological agents, transplanted organs or the body’s own cells or tissue. The term ‘tolerogenic’ refers to the immune system’s selective tolerance of a specific pathogenic or immunostimulatory antigen following treatment with Idogen’s cell therapy. Idogen’s most advanced product candidate, IDO 8, is designed for patients with severe hemophilia A who have developed neutralizing antibodies against their life-saving therapy with coagulation factor VIII (FVIII). The company is also developing IDO T – a tolerogenic cell therapy to prevent transplanted organ rejection, initially in kidney transplantation with a living donor. IDO T is expected to improve transplant survival and reduce the need for immunosuppressive drugs, which will reduce the risk of cancer and infections. A third therapeutic area that Idogen regards as especially interesting is IDO AID, for the treatment of various types of severe and unusual autoimmune diseases.
Idogen’s most advanced product candidate, IDO 8, is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII).
The company also develops IDO T – a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection. IDO T is expected to reduce the need for immunosuppressive drugs and improve transplant survival, thereby reducing the risk of cancer and infections.
Idogen recently added a third therapeutic area in autoimmune diseases, IDO AID, to its project portfolio.